🔗 Share this article

As America continues making unprecedented adjustments to its vaccination recommendations, a particular individual has emerged in a surprising turn: Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by casting doubt on Covid vaccines throughout the global health crisis and has focused upon potential deaths after Covid vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Shifts to Childhood Vaccine Schedule

Agency leaders were set to unveil radical revisions to the pediatric immunization program recently, synchronizing the US with Denmark’s immunization schedule, it is understood – a significant shift that would put the US at odds with many the international standard with little proof for benefit. The announcement has been delayed until the new year.

In place of Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the event. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this year.

A New Direction at the Regulatory Body

Høeg's temporary position may indicate a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad solidify control at the FDA – and it signals a renewed priority upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing certain childhood shot schedules in the US in order to be more like Denmark, a country with universal health coverage and a number of inhabitants roughly the size of Wisconsin’s.

In her initial public appearances, she has continued to focus on vaccines – typically the responsibility of Dr. Prasad, chief of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Qualifications

Høeg has no obvious track record in pharmaceutical research, approval processes or management, which has been standard for past leaders of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and CBER since spring.

“It seems she lacks to have the necessary background” for overseeing the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a sizeable institution. She has no expertise in drug approvals.”

Past directors of CBER would “be deeply familiar with legal statutes and the science of medication creation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that prior appointees who led the center have had.”

The drug center has an vast workload at the agency, she emphasized.

“The public just focuses on the novel medication approvals, but the generic program approves numerous generic drugs. There is also a biosimilars division, non-prescription drug unit and more, and every single one must be looked after,” she noted. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a major leadership component to the job, which supervises in excess of 5,000 personnel. “It’s a enormous administrative position, if you execute it properly,” the former official added.

Agency Reaction and Controversial Policies

When asked about inquiries about Dr. Høeg's qualifications and whether this assignment indicates increased cooperation among agency officials on vaccines, a press secretary stated that the “questions are based on flawed assumptions”.

“Her experience is consistent with the responsibilities of her position,” the spokesperson said, pointing to the months Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Høeg takes over the agency head's controversial fast-track approval initiative, a contentious rapid drug-approval program that allegedly concerned her predecessors. “How are these drugs being chosen for this expedited pathway? Who is making the choices?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the FDA right now.”

Broadly speaking, he said, “the agency looks to be trending towards more relaxed rules of all drugs, with the exception of vaccines.”

Established Past Work on Vaccines

Regarding immunizations, Høeg has a more documented, if concerning, past, Howard observe. She authored a analysis using non-validated volunteer-provided data to estimate the frequency of myocarditis after Covid vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccinations are pose a greater threat than they are.

Part of her “desired changes” for the new federal leadership included altering rules for novel immunizations and discontinuing “non-essential” vaccines, she remarked following the vote on a podcast. At the agency, Høeg has allegedly floated the idea of preventing adolescent males from receiving Covid vaccines.

“She is an thorough true believer who commences with her conclusions and reverse-engineers to retrofit the science in a highly deceptive, untruthful way,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg joined other skeptics, {like|